GSK Wins Expanded U.S. Approval for Arexvy RSV Vaccine in High-Risk Adults Under 50

GlaxoSmithKline ( (GB:GSK) ) just unveiled an update.

GSK has secured expanded U.S. approval for its RSV vaccine Arexvy, which can now be used in adults aged 18 to 49 who are at increased risk for RSV-related lower respiratory tract disease, adding to its prior indications in older and high-risk populations. The decision, backed by Phase IIIb immunogenicity and safety data showing non-inferior immune response and a consistent safety profile, broadens access for an estimated millions of higher-risk younger adults and strengthens GSK’s competitive position in the RSV vaccine market while supporting long-term growth through wider global regulatory submissions.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK is a global biopharmaceutical company focused on vaccines and specialty medicines, leveraging science and technology to prevent and treat disease worldwide. The company has a significant presence in respiratory and infectious disease prevention, with its RSV vaccine Arexvy forming a key part of its adult vaccine portfolio and growth strategy.

Average Trading Volume: 8,933,818

Technical Sentiment Signal: Buy

Current Market Cap: £81.34B

See more insights into GSK stock on TipRanks’ Stock Analysis page.